Clinical Trials Logo

Pyelonephritis clinical trials

View clinical trials related to Pyelonephritis.

Filter by:

NCT ID: NCT06299215 Not yet recruiting - Pyelonephritis Clinical Trials

Factors and Prognosis of Obstructive Pyelonephritis Patients

PYELO-OBS
Start date: March 1, 2024
Phase:
Study type: Observational

Acute obstructive pyelonephritis is a condition with a high risk of complications and may require admission to the intensive care unit. Most of the available data on this condition comes from small, retrospective, single-centre series. To date, no large-scale study has examined the factors associated with the prognosis of patients admitted to intensive care for acute obstructive pyelonephritis. The aim of this study is to describe the population and prognosis of patients admitted to the intensive care unit for the management of acute obstructive pyelonephritis, and to identify factors associated with a poor prognosis in these patients.

NCT ID: NCT06144060 Not yet recruiting - Clinical trials for Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis

Start date: December 2023
Phase: Phase 2
Study type: Interventional

The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS -8427 in patients with complicated urinary tract infection, including acute pyelonephritis.

NCT ID: NCT06141395 Recruiting - Pneumonia Clinical Trials

NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification

BIOARTE
Start date: November 16, 2023
Phase:
Study type: Observational

Rapid detection of microorganisms is a promising approach towards early administration of appropriate antibiotics for sepsis. This study aims to investigate the potential of a new NGS platform for the rapid diagnosis of circulating bacteria in blood.

NCT ID: NCT06128213 Not yet recruiting - Clinical trials for Urinary Tract Infections

NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis

Start date: March 31, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical study is to test NRX101 in participants with complicated urinary tract infections including pyelonephritis. The main questions it aims to answer are: - Does NRX101 help participants resolve UTIs? - Is NRX101 safe for participants with UTIs? Participants will be seen in a doctor's office approximately 6 times to: - Answer a short 10 item questionnaire. - Review of side effects - Urine tests - Blood draw (about 10 ml or 2 teaspoons) - Review of medications - Review any signs or symptoms of UTI - Vital signs and weight (including blood pressure, heart rate, respiratory rate, and temperature) - Review of medical history This is an open-label study of NRX101, which means both you and your doctor know what drug you are taking. After the study is completed, researchers will look at the data to see if NRX101 helps participants with complicated UTI's.

NCT ID: NCT06127160 Not yet recruiting - Clinical trials for Pyelonephritis Acute

Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis

Start date: January 2024
Phase: Phase 4
Study type: Interventional

This pilot study will randomize 40 female patients with acute uncomplicated pyelonephritis to receive standard duration of therapy versus patient-directed antimicrobial duration (PDAD). The primary objectives of this pilot trial are to determine the feasibility and safety of conducting a full-scale multi-center randomized controlled trial.

NCT ID: NCT06059846 Recruiting - Clinical trials for Urinary Tract Infection

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

PIVOT-PO
Start date: December 21, 2023
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication) at the Test-of-Cure (TOC) visit in hospitalized adult participants (≥18 years of age) with cUTI or AP.

NCT ID: NCT05905055 Recruiting - Clinical trials for Acute Pyelonephritis

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

Integral-2
Start date: September 22, 2023
Phase: Phase 3
Study type: Interventional

This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the treatment of patients with cUTI, AP, HABP, VABP, and cIAI, due to Carbapenem Resistant Enterobacterales.

NCT ID: NCT05887908 Recruiting - Clinical trials for Acute Pyelonephritis

Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

Integral-1
Start date: May 23, 2023
Phase: Phase 3
Study type: Interventional

Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).

NCT ID: NCT05674032 Recruiting - Clinical trials for Acute Pyelonephritis

Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis

Start date: June 24, 2020
Phase:
Study type: Observational

The project aims to investigate bacterial metallophores as potential diagnostic markers of acute pyelonephritis and complicated urinary tract infections. These secondary metabolites are excreted by pathogenic microorganims in the course of infection for the uptake of iron and other metallic ions from the host. They are species-specific and can be detected in body fluids (including urine) by mass spectrometry. The potential contribution of this project is a culture-independent method for the diagnosis of the causative microbiological agent.

NCT ID: NCT05597540 Recruiting - Clinical trials for Kidney Transplant Infection

Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.

SHORTCUT
Start date: February 22, 2024
Phase: Phase 3
Study type: Interventional

Infections are a major cause of morbidity and mortality in solid organ transplant recipients. In kidney transplant recipients (KTR) urinary tract infection (UTI) represent 45-72% of all infections, and 30% of all hospitalizations for sepsis. Acute transplant pyelonephritis are the most common complications occurring in more than 20% of patients, mainly in the first year after transplantation. They are associated with an increased risk of acute kidney rejection and long-term kidney graft dysfunction. Gram-negative bacteria, mainly E. coli, account for more than 70% of UTI in KTR. As those infections are favoured by urinary tract modifications/defects and immunosuppression, they are often recurrent and necessitate repeated courses of antibiotics. Selective pressure due to antibiotic consumption, along with frequent hospital admissions and immunosuppression, are well known risk factors for the development of antibiotic resistant infections. Multidrug (MDR)- or extensively (XDR)- drug resistant Enterobacteriaceae including ESBL- or carbapenemase-producing organisms, are thus increasingly observed in transplant units and represent a global threat as very few new antibiotics are expected in the next decade. One main strategy to limit antimicrobial resistance is to reduce the duration of antibiotic treatment. A 7 day-course is recommended for simple acute pyelonephritis (APN) treated with fluoroquinolones or parenteral B-lactams, prolonged up to 10 or 14 days in the presence of underlying disease at risk of complications. Most KT teams treat patients between 14-21 days as recommended by American guidelines. However, the need to extend treatment duration in immunosuppressed patients is a poorly defined concept and the optimal duration of treatment for APN in KTR is not known as these patients are excluded from most studies. As there is an urgent need to reduce antibiotic consumption in this population at high risk of developing infections due to resistant pathogens, the hypothesis is that a 7 day-treatment is sufficient to cure APN with good clinical response after 48h of treatment in KTR and is as effective as 14 days.